Rivaroxaban versus standard anticoagulation for the treatment of pulmonary embolism: a real-life study

Conclusion: Riva appears to be effective and safe to treat PE in a non-selected population with a shorter LOS.

Source: European Respiratory Journal - November 20, 2019 Category: Respiratory Medicine Authors: Vigneron, C., Vivot, A., Jamme, M., Gibelin, A., Briend, G., Pastre, J., Planquette, B., Meyer, G., Sanchez, O. Tags: Pulmonary embolism Source Type: research